Loading
Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide.
Jiangsu Hengrui's rezvilutamide (SHR3680) received NMPA approval in June 2022 for high-volume metastatic hormone-sensitive prostate cancer with androgen deprivation, after the CHART phase 3 trial showed longer radiographic progression-free and overall survival than bicalutamide. Further phase 3 trials in non-metastatic and castration-resistant disease are registered. It is not approved outside China.
A second-generation antagonist of the androgen receptor, the class of enzalutamide, apalutamide and darolutamide, blocking androgen signalling in prostate cancer cells. Connects to Androgen receptor.
1.Rezvilutamide acts on Androgen receptor, the hormone receptor or the enzyme that makes the hormone.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2022 | High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Rezvilutamide" OR ABSTRACT:"Rezvilutamide" OR TITLE:"SHR3680" OR ABSTRACT:"SHR3680") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rezvilutamide, not a curated reading list.
Shares Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Androgen receptor, Prostate cancer and the tag pipeline.
Shares Androgen receptor, Prostate cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Androgen receptor, Prostate cancer and the tag pipeline.
Shares A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer, Jiangsu Hengrui Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.